Raymond James raises Kymera Therapeutics target to $144 from $140
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Intel outlook raises new doubts about earnings recovery
A Street View report says Intel's outlook has raised new questions about its earnings recovery, citing weakness in the PC market, manufacturing problems and expansion costs.
M impact | EQUITY | Oct 30, 2026, 09:58 AM UTC
JPMorgan Downgrades First Industrial Realty Trust to Neutral, Sets $60 Target
JPMorgan cut its rating on First Industrial Realty Trust to Neutral from Overweight and set a $60 price target.
M impact | EQUITY | Oct 30, 2026, 09:56 AM UTC
AstraZeneca Reports Q3 Results Beat, Launches $1.5 Billion Annual Savings Plan
AstraZeneca shares rise after Q3 results beat; the company launched an annual savings plan worth $1.5 billion.
M impact | EQUITY | Oct 30, 2026, 09:56 AM UTC
AI Stock Selloff Deepens as Nasdaq Futures Fall More Than 2%
Nasdaq futures fell more than 2% after quarterly results from Intel and Amazon rocked confidence in artificial-intelligence stocks. Treasury yields fell to multiweek lows as invest
M impact | EQUITY | Oct 30, 2026, 09:55 AM UTC
JPMorgan Downgrades Coursera to Neutral, Sets $5 Price Target
JPMorgan downgraded Coursera to Neutral from Overweight and set a $5 price target.
M impact | EQUITY | Oct 30, 2026, 09:54 AM UTC
Intel Shares Plummet Premarket After Q3 Revenue Miss and Weak Q4 Outlook
M impact | EQUITY | Oct 30, 2026, 09:54 AM UTC